The Diagnostic Value Of Systemic Inflammatory Markers Including Halp Score In Differentiating Pterygium And Conjunctival Intraepithelial Neoplasia
Published 2026 - 44th Congress of the ESCRS
Reference: PP23.02 | Type: Free paper | DOI: 10.82333/xap3-t432
Authors: Dr Gozde Sahin Vural* 1 , Dr Gozdenur Verdil 1
1Ophthalmology,Balıkesir University,Balıkesir,Türkiye
Purpose
To investigate whether systemic inflammatory markers, including the hemoglobin–albumin–lymphocyte–platelet (HALP) score, can differentiate benign pterygium from conjunctival intraepithelial neoplasia (CIN) and to evaluate their potential role as adjunctive biomarkers in the benign–premalignant spectrum of ocular surface lesions.
Setting
Single-center retrospective comparative study conducted at a tertiary ophthalmology clinic.
Methods
Patients were divided into three groups: control, pterygium, and CIN. Hematologic and biochemical parameters were retrieved from medical records. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), lymphocyte-to-monocyte ratio (LMR), C-reactive protein (CRP), albumin, hemoglobin–albumin–lymphocyte–platelet (HALP) score, and CRP-based Glasgow Prognostic Score (GPS and modified GPS) were calculated. Group comparisons were performed using one-way ANOVA.
Results
Mean NLR values were 3.40±4.02 in controls, 2.12±0.94 in pterygium, and 3.33±2.04 in CIN (p=0.164). Mean PLR was 136.36±59.04, 123.62±52.29, and 124.72±72.53 (p=0.672), while mean SII was 973.86±1463.89, 571.72±332.89, and 748.83±459.47 (p=0.284). LMR, CRP, albumin, GPS, and mGPS showed no significant differences (all p>0.05). Mean HALP scores were 0.523±0.220, 0.567±0.267, and 0.626±0.290 in the three groups, respectively, with no statistically significant intergroup difference (p=0.464).
Conclusions
Systemic inflammatory markers, including NLR, PLR, SII, LMR, CRP, albumin, HALP score, GPS, and mGPS, did not demonstrate significant differences between pterygium and CIN. The addition of HALP did not improve diagnostic discrimination. Hematologic parameters alone do not appear to be reliable tools for differentiating benign from premalignant ocular surface lesions. In clinically suspicious cases, biopsy remains the gold standard for definitive diagnosis.